Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/23/2026, 12:00:00 AM
Announced positive phase 3a results for oral semaglutide in children with type 2 diabetes. Medium importance as it expands the market for a key drug, expected.
Korean Translation
소아 당뇨 환자 대상 경구용 세마글루타이드의 임상 3a상 성공 발표임. 시장 확대 가능성에 따라 중간 중요도로 예상됨.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon's Q1 2026 earnings release is scheduled for June 4, 2026, with analysts forecasting weak results following previous guidance. Earnings releases typically result in a >5% price impact, justifying a Medium importance, scheduled.
6/4/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time is scheduled to release its Q1 2026 financial results before market open on May 5, 2026. Importance is Medium as earnings releases typically result in price movements exceeding 5%, scheduled.
5/5/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled
4/30/2026, 12:00:00 AM